Manila Times Business
Clearmind Medicine to Feature New Insights from CMND-100 Psychedelic Clinical Trial on "Inside MEAI” Webinar
Yale and Johns Hopkins Researchers to Present Early Findings on MEAI Next Week in Live Webinar Register now for free and join on June 10, 2026 Vancouver, Canada, June 05, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) ("Clearmind” or the "Company”), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced it will host
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
BC-Driven Breakthrough: TCL Solar's Value Leap from Wafer Leadership to Tier 1 Module Supplier
1h ago
Making Sustainability Count on World Environment Day: How Beko Focuses on Lowering Water and Energy Consumption from Factories to Homes
1h ago
Independent Market Research Finds Strong Physician Intent to Prescribe Moleculin's Annamycin in Relapsed/Refractory AML
1h ago
PropMarket Launches as the First Prop Firm Built for Prediction Markets
1h ago